Eli Lilly (NYSE: LLY) has been a terrific investment in recent years. Thanks to significant clinical progress and outstanding ...

Camurus AB reported its second-quarter earnings for 2025, revealing a robust financial performance with earnings per share (EPS) of 4.08, significantly surpassing the forecasted 3.27. The company ...

Camurus AB (CAMRF) reports a 52% revenue increase, strategic licensing with Eli Lilly, and EU approval of Oczyesa, despite currency challenges and market hurdles.

Camurus AB (STO:CAMX) presented its second quarter 2025 results on July 17, revealing record financial performance and significant progress across its product portfolio.

Camurus AB (STO:CAMX) presented its second quarter 2025 results on July 17, revealing record financial performance and significant progress across its product portfolio. The Swedish specialty ...

Camurus AB reported its second-quarter earnings for 2025, revealing a robust financial performance with earnings per share (EPS) of 4.08, significantly surpassing the forecasted 3.27. The company’s ...

Baxdrostat is a highly selective, second-generation, nonimidazole aldosterone synthase inhibitor; 100 times less baxdrostat ...

Post-operative nausea and vomiting (PONV) market to rise from $2.11B in 2024 to $2.97B in 2029, driven by innovations in ...

View the latest Camurus AB (CAMRF) stock price, news, historical charts, analyst ratings and financial information from WSJ.

The neuroendocrine prostate cancer treatment space will experience significant changes during the forecast period of 2025–2034, owing to the launch o ...

An investigational antihypertensive drug resolved or reduced hypertension in patients with primary aldosteronism, according to a small phase IIa trial. By week 12, systolic blood pressure was ...